STAAR Surgical Co (STAA) Stock Analysis

Verdict: WATCH (do not buy)

Post-merger collapse, China sales volatility, and sub-2% net margins outweigh revenue recovery, keeping the model cautious.

Investment score: 46/100

Analysis as of

Is STAAR Surgical Co stock worth reviewing? The TradeMates thesis

The TradeMates model evaluates STAAR Surgical as a WATCH, balancing robust gross margins (76.6%) and strong Q1/Q2 2026 revenue rebound against sky-high valuation (P/E 278x) and post-merger operational uncertainty.

7-factor investment score

STAAR Surgical Co opportunities and risks

What speaks for STAA

What speaks against STAA

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
STAA278.3x3.3x30.3x76.2%1.1%-0.6%
XRAYn/a0.5x41.2x49.5%-15.0%8.1%
NEOGn/a3.0x31.2x47.4%-6.3%1.9%
UFPT31.8x3.6x20.9x28.5%11.4%2.7%
BVS17.2x1.6x11.3x68.0%9.4%10.0%
KIDSn/a2.3xn/a73.7%-15.7%-0.3%
Peer mediann/a2.3x20.9x49.5%-6.3%2.7%

Frequently asked questions about STAAR Surgical Co (STAA)

Is STAA stock a good investment?

The TradeMates model rates STAAR Surgical Co as WATCH (do not buy) with an investment score of 46/100. The TradeMates model evaluates STAAR Surgical as a WATCH, balancing robust gross margins (76.6%) and strong Q1/Q2 2026 revenue rebound against sky-high valuation (P/E 278x) and post-merger operational uncertainty. This is algorithmic model output, not personal investment advice.

Is STAA stock a buy?

The TradeMates model verdict for STAA is WATCH (do not buy) with an investment score of 46/100. Treat this as a model signal to review, not a personal buy recommendation.